Coronavirus disease 2019 (COVID-19) poses substantial challenges to social life and health-care systems across the world. Because there is no specific treatment against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), repurposing of antimicrobial agents remains a mainstay in managing COVID-19 patients. However, the expanded use of broad-spectrum antibiotics carries significant risks of antimicrobial resistance while managing COVID-19 patients. In this context, the World Health Organization (WHO) has recommended preventive and precautionary measures, such as social distancing, self-isolation, hand hygiene, and lockdowns, as effective disease containment modalities during the pandemic. ^{Reference Misbah, Ahmad and Butt1,Reference Mallhi, Ahmad and Butt2}

Existing data demonstrates that COVID-19 is associated with secondary infections, such as pulmonary pneumonia and ventilator-associated pneumonia. ^{Reference Zhou, Yu and Du3} In the case of secondary infections, use of antimicrobials is the only treatment strategy left for physicians, especially for suspected bacterial infections. ^{Reference Arthur, Kizor and Selim4} The crisis of antimicrobial resistance (AMR) is becoming devastating with each passing year, which has cautioned health-care providers to be judicious with the use of antimicrobial agents. ^{Reference Park and Murthy5,Reference Miranda, Silva and Capita6} The current COVID-19 pandemic threatens to further jeopardize the use of available antimicrobial agents as treatment strategies.

Following the H1N1 influenza outbreak in 2009, several environmental microbiologists warned that the excessive use of antibiotics might lead to an increase in resistant bacterial infections, while during the current COVID-19 pandemic, many cases were treated excessively with antibiotics. ^{Reference Zhou, Yu and Du3} The majority of COVID-19 patients are either asymptomatic or may experience mild to moderate illness without bacterial infection. ⁷ However, uncertainty among health-care professionals about the prudent use of antibiotics among COVID-19 patients is an intimidating factor in terms of additional health-care costs, especially for countries with limited resources and poor quality of health services. ^{Reference Malik, Atif and Hashmi8} Unnecessary antibiotic use in viral diseases and epidemics is leading to an increased AMR and, thus, has amplified the financial burden. ^{Reference Ventola9} Because AMR has already been declared as a global emergency, health-care professionals need to be careful with the use of antimicrobial agents for the treatment of secondary infections that may arise during the course of COVID-19 and other viral diseases.

Implementation of antimicrobial stewardship programs (ASPs) has been associated with decreased antibiotic use and reduced costs, ^{Reference Brink, Messina and Feldman10} which ultimately reduces the AMR burden. WHO’s interim guidelines on the clinical management of COVID-19 suggest the integration of ASPs in the health-care system. These guidelines have discouraged the use of antibiotics in mild or moderate COVID-19 patients without symptoms of a bacterial infection. However, antibiotics classified in WHO’s AWaRe (access, watch, reserve) category, such as co-amoxicillin, could preferably be used in geriatrics and pediatrics. ^{Reference Getahun, Smith and Trivedi11}

Health-care authorities and professionals should take hard lines to implement and practice the WHO’s guidelines during management of COVID-19 patients.¹² Prolonged stay of patients in hospitals resulting from secondary and super-infections may further put unnecessary strain on health-care systems. A multipronged approach using evidence-based practices should be considered for treatment of COVID-19 patients. In addition, compliance with the WHO’s Global Action Plan on AMR is of utmost importance. This can help reduce the additional health-care costs and burden on overwhelmed health-care systems.

Periodic sensitivity testing will help to ascertain the pattern of prevailing AMR so that timely and effective combat strategies can be initiated. Pharmacists and other health-care professionals can play a pivotal role in implementation of ASPs to reduce the injudicious use of antimicrobials during the current COVID-19 pandemic. In a nutshell, appropriate ASP implementation and monitoring can help allocate resources to manage global public health crises effectually.